Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity, Inc.'s SEC filings document operating results, governance matters and capital-structure disclosures for a Massachusetts-incorporated life sciences and diagnostics company. Its 8-K reports furnish quarterly and annual financial results, preliminary performance updates, Regulation FD investor presentation materials and other material-event disclosures.
Proxy and annual-meeting filings describe director elections, auditor ratification, advisory executive-compensation votes and shareholder-approved bylaw amendments, including the ability of holders of 25% of the company's stock to call a special meeting. Other current reports identify registered securities, including RVTY common stock and 1.875% notes due 2026 listed on the New York Stock Exchange, as well as officer appointments and related governance changes.
Barrett Peter reported acquisition or exercise transactions in this Form 4 filing.
REVVITY, INC. director Peter Barrett reported two equity compensation awards of common stock on May 7, 2026. He received grants covering a total of 2,280 restricted stock units, with each unit representing a contingent right to one share of common stock at no cash cost.
The restricted stock units will fully vest on April 27, 2027, the scheduled date of the next annual shareholder meeting. Vesting is subject to his continued service, or may occur earlier upon death, disability, qualifying retirement, or if his service ends within 12 months after a change in control.
Revvity, Inc. reported higher first quarter 2026 results and outlined plans to divest its China Immunodiagnostics business. Revenue rose to $711 million from $665 million, a 7% increase, with 3% organic growth. GAAP EPS from continuing operations was $0.37, up from $0.35, while adjusted EPS reached $1.06 versus $1.01 a year earlier. Pro forma revenue excluding the China Immunodiagnostics business was $687 million, with pro forma organic growth of 6%.
The company signed a letter of intent to sell the China Immunodiagnostics business, which represented about 6% of 2025 revenue, for up to $200 million, with closing targeted for 2027 subject to conditions and approvals. On a pro forma basis, Q1 GAAP EPS from continuing operations was $0.40 and adjusted EPS was $1.04. Revvity now forecasts full year 2026 pro forma revenue of $2.81–$2.84 billion, pro forma organic revenue growth of 3%–4%, and pro forma adjusted EPS of $5.20–$5.30.
Revvity, Inc. reported results of its annual shareholder meeting and a governance change. Shareholders approved an amendment to the Amended and Restated By-laws to allow shareholders owning 25% of the company’s common stock to call a special meeting, effective April 28, 2026.
All ten director nominees were elected, each receiving over 90 million votes in favor. Shareholders also ratified Deloitte & Touche LLP as independent auditor, approved on an advisory basis the company’s executive compensation, and backed the new special meeting right. A shareholder proposal on executive stock ownership was rejected, with 22,974,850 votes for and 76,502,157 against.
Revvity Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 8,326,862 shares of Revvity common stock, representing 7.44% of the class as of 03/31/2026. The filing states these holdings include securities held by Vanguard funds and managed accounts over which Vanguard exercises dispositive power.
REVVITY, INC. Vice President and Chief Accounting Officer Anita Gonzales reported an open-market sale of 80 shares of common stock at $92.80 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025, and left her holding 7,319 shares directly.
RVTY submitted a Form 144 notice proposing the sale of 80 common shares. The filing shows an aggregate value of $7,424.00, references the NYSE, and includes transaction origins such as an ESPP purchase (12/31/2021) and restricted stock vesting (04/15/2022). The form lists 04/20/2026 in the header.
Revvity Inc Schedule 13G/A amendment discloses that The Vanguard Group reports 0 shares beneficially owned of Revvity common stock, representing 0% of the class. The filing explains this follows an internal realignment and reliance on SEC Release No. 34-39538 (January 12, 1998), with certain Vanguard subsidiaries reporting separately.
REVVITY, INC. reported that officer Anita Gonzales received new equity awards as part of her compensation. She was granted a non-qualified stock option for 4,576 shares of common stock at an exercise price of $86.635 per share, expiring on March 16, 2033, which is scheduled to fully vest on the second anniversary of the grant date.
She also received 1,600 time-based restricted stock units that are scheduled to fully vest on the second anniversary of the grant date. After this award, her direct common stock holdings total 7,399 shares. These are grants and awards, not open-market purchases.
Revvity, Inc. is asking shareholders to vote at its 2026 annual meeting, which will be held virtually via live webcast on April 28, 2026 at 8:00 a.m. Eastern Time. Shareholders of record at the close of business on March 2, 2026, when 111,803,327 common shares were outstanding and entitled to vote, may participate and vote online using a control number.
The agenda includes electing ten directors for one-year terms, ratifying Deloitte & Touche LLP as independent registered public accounting firm for fiscal 2026, a non-binding advisory vote on executive compensation, an amendment to the By-laws to allow shareholders owning 25% of stock to call a special meeting, and a shareholder proposal on executive stock ownership. The board recommends voting FOR Proposals 1–4 and AGAINST Proposal 5.
The board has ten members, nine of whom are independent, with an independent non-executive chair and fully independent audit, compensation and nominating committees. In 2025, Deloitte & Touche LLP received total fees of $5,620,000, and non-employee directors generally received a $90,000 cash retainer plus stock and RSU awards targeted at $225,000 in aggregate value, with higher amounts for the chair and committee leaders.